Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Equity Income (2024 - 2025)

Addex Therapeutics' Equity Income history spans 2 years, with the latest figure at -$1.3 million for Q4 2025.

  • On a quarterly basis, Equity Income rose 46.99% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $942.6 billion, a N/A change, with the full-year FY2025 number at -$4.8 million, down 92.71% from a year prior.
  • Equity Income came in at -$1.3 million for Q4 2025, down from -$1.1 million in the prior quarter.
  • The five-year high for Equity Income was $942.6 billion in Q1 2025, with the low at -$2.5 million in Q4 2024.